Envudeucitinib for Plaque Psoriasis
Transcriptomic Modulation in Psoriatic Skin Following Envudeucitinib Treatment: A Subgroup Analysis of a Phase 2 STRIDE Trial Skin Tape Strips
6th Inflammatory Skin Disease Summit
November 13, 2025
Achievement of Treat-to-Target Thresholds with Envudeucitinib, a Selective TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis: Results from STRIDE and OLE
2025 Fall Clinical Dermatology Conference
October 23, 2025
Safety and efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the Phase 2 STRIDE study
Journal of the American Academy of Dermatology (JAAD)
October 6, 2025
Highly selective, allosteric inhibition of TYK2 with oral envudeucitinib in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging phase 2 study
Journal of the American Academy of Dermatology (JAAD)
July 12, 2025
Efficacy and Safety of envudeucitinib, a Highly Selective Oral TYK2 inhibitor, in Moderate-to-Severe Plaque Psoriasis: Long-term Phase 2 Results
American Academy of Dermatology (AAD) Annual Meeting
March 8, 2025
Patient-Reported Outcomes in the Phase 2 Studies of Envudeucitinib, an Oral Allosteric TYK2 Inhibitor, in Adults with Moderate-to-Severe Plaque Psoriasis
American Academy of Dermatology (AAD) Annual Meeting
March 7, 2025
Pharmacokinetics, Safety, and Tolerability of Envudeucitinib, an Allosteric TYK2 Inhibitor for Plaque Psoriasis: Evaluation in Asian Populations Compared to Caucasians
American Academy of Dermatology (AAD) Annual Meeting
March 7, 2025
Envudeucitinib, an Allosteric TYK2 Inhibitor, Modulates Disease and TYK2-related Pathway Transcriptomic and Proteomic Biomarkers in Psoriasis STRIDE Trial Patients
American Academy of Dermatology (AAD) Annual Meeting
March 7, 2025
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral allosteric TYK2 inhibitor envudeucitinib using a randomized, double-blind, placebo-controlled study design
Clinical and Translational Science
November 27, 2024
Envudeucitinib, An allosteric TYK2 Inhibitor, Downregulates Biomarkers of Disease and TYK2 Activity
European Academy of Dermatology & Venereology (EADV) Congress
September 27, 2024
Efficacy and Safety of Envudeucitinib, a Highly Selective Oral TYK2 Inhibitor, in Moderate-toSevere Plaque Psoriasis: Phase 2 results through Week 28
European Academy of Dermatology & Venereology (EADV) Congress
September 27, 2024
Patient-Reported Outcomes in the Randomized, Double Blind Phase 2 Study of Envudeucitinib, an Oral Allosteric TYK2 Inhibitor, in Adults with Moderate-to-Severe Plaque Psoriasis
European Academy of Dermatology & Venereology (EADV) Congress
September 25, 2024
Exploratory Exposure Response (E-R) Analysis of Envudeucitinib, An allosteric oral TYK2 inhibitor, in Patients with Psoriasis
European Academy of Dermatology & Venereology (EADV) Congress
September 25, 2024
Efficacy and Safety of Envudeucitinib, a Highly Selective Oral TYK2 Inhibitor, in a Phase 2 Study in Adults with Moderate-to-severe Plaque Psoriasis (STRIDE)
American Academy of Dermatology (AAD) Annual Meeting
March 9, 2024
Pharmacokinetic and Pharmacodynamic Characteristics of Envudeucitinib, an Oral Allosteric TYK2 Inhibitor, in Phase 1 Healthy Volunteer Trials
American Academy of Dermatology (AAD) Annual Meeting
March 9, 2024
Envudeucitinib for Lupus (SLE)
Envudeucitinib, an Allosteric TYK2 Inhibitor, Maximally Suppresses Type 1 Interferon, a Therapeutic Pathway Central to SLE and CLE
ACR Convergence 2024
November 18, 2024
Novel Role of TYK2 mechanism in SLE Pathogenesis via T Cell and B Cell Pathways
ACR Convergence 2024
November 17, 2024
Lonigutamab
Preliminary Safety, Efficacy, and Quality of Life Outcomes of Subcutaneous Lonigutamab (Anti–Insulin-Like Growth Factor 1 Receptor [IGF-1R]) from a Phase 1/2 Proof of Concept Study in Patients with Thyroid Eye Disease
European Society of Ophthalmic Plastic and Reconstructive Surgery (ESOPRS) Annual Meeting
September 14, 2024
Preliminary Safety and Efficacy of Subcutaneous Lonigutamab (Anti–IGF-1R) From a Phase 1/2 Proof of Concept Study in Patients with Thyroid Eye Disease
Endocrine Society (ENDO) Annual Meeting
May 31, 2024
A First-in-Human Phase 1 Randomized, Single-Ascending Dose Study of Lonigutamab, an Anti-IGF-1R Monoclonal Antibody, in Healthy Volunteers
North American Neuro-Ophthalmology (NANO) Society Annual Meeting
March 11-16, 2023
A-005
Pharmacokinetics, Pharmacodynamics, and CNS Penetration of A-005: A Novel TYK2 Inhibitor for MS
European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress
September 24, 2025
Safety, Tolerability, and Pharmacokinetics of A-005: A Selective Brain-Penetrant TYK2 Inhibitor for CNS Inflammatory Diseases in Healthy Volunteers Following Single and Multiple Ascending Doses
Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum
February 28, 2025
A-005, A Selective Oral Brain Penetrant TYK2 Inhibitor, Modulates Astrocytes and Microglia
Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum
February 28, 2025
A Selective, Allosteric TYK2 Small-molecule Inhibitor Modulates Immune Cell Functions and Ameliorates Experimental Autoimmune Encephalomyelitis
Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum
March 1, 2024